Erratum  by unknown
Announcements 907
gress of Nephrology. For more information, write Professor F.
0. Simpson, Welicome Medical Research Institute, P.O. Box
913, Dunedin, New Zealand.
An International Symposium on Clinical Disorders of Bone
and Mineral Metabolism will be held at the Henry Ford
Hospital in Michigan May 9—13, 1983. The symposium will
focus on current clinical problems in metabolic bone disease
and related disorders. For information write Dr. B. Frame, 5th
Medical Division, Henry Ford Hospital, 2799 W. Grand Blvd.,
Detroit, Michigan 48202, USA.
The Sixth International Symposium of Paediatric Nephrolo-
gy will be held in Hannover, Federal Republic of Germany,
August 29—September 2, 1983. For more information, write
Professor J. Brodehl, Kinderklinik, Medizinische Hochschule
Hannover, Karl-Wiechert-Allee 9, 3000 Hannover 61, Federal
Republic of Germany.
The Second International Symposium on the Glomerular
Basement Membrane will be held in Vienna, Austria, on
September 5—9, 1983. For more information write Prof. Gert
Lubec, Department of Pediatrics, University of Vienna, Wäh-
ringer Gürtel 74-76, A-1090 Vienna, Austria.
The International Congress of Noninvasive Diagnosis of
Kidney Disease Will be held in Vienna, Austria, on September
12—16, 1983. For more information write Prof. Gert Lubec,
Department of Paediatrics, University of Vienna, Wahringer
Gürtel 74-76, A-1090 Vienna, Austria.
The IX International Congress of Nephrology will be held
June 11—16, 1984, in Los Angeles, California, USA. For further
information, write the International Congress of Nephrology,
do UCLA School of Medicine, 1000 Veteran Avenue, Room
31—76, Los Angeles, California 90024, USA.
Applications are invited for the XI Congress of the Interna-
tional Society of Nephrology in 1990. The 1984 Congress will be
held in Los Angeles and the 1987 Congress in London. The
Society wishes to encourage invitations for the 1990 Congress
from outside Europe and North America. Formal applications
must be received by 1984. Interested National Societies of
Nephrology should contact the Secretary General for the re-
quired application forms: Dr. John F. Moorhead, Secretary
General, International Society of Nephrology, do Department
of Nephrology and Transplantation, The Royal Free Hospital,
Pond Street, London NW3 2QG, England.
American Society of Nephrology
The American Society of Nephrology announces a new
service to their non-American colleagues: For a fee of US
$30.00 the ASN will include you on all its mailings and
announcements, including a copy of the annual program book.
Checks for $30.00 along with your name and desired mailing
address should be sent to ASN National Office, do Charles B.
Slack, Inc., 6900 Grove Road, Thorofare, New Jersey 08086,
USA.
NIH study of rapidly progressive glomerulonephritis
The National Institute of Arthritis, Diabetes, Digestive and
Kidney Diseases requests the assistance of physicians in refer-
ring patients to participate in a controlled trial of "Steroid and
Immunosuppressive Drug Therapy in Idiopathic Crescentic
Glomerulonephritis." Patients with active glomerulonephritis
plus deteriorating renal function andlor severe crescent forma-
tion who have had evidence of nephritis for no more than 3
months are eligible. Following initiation of protocol therapy
which includes tapering oral prednisone plus monthly pulse
injections of either methylprednisolone or cyclophosphamide,
patients may receive subsequent treatment by the referring
physicians. For inquiries, write Dr. James E. Balow or Dr.
Howard A. Austin, National Institutes of Health, Bldg. 10, Rm.
3N-112, Bethesda, Maryland 20205, USA, or phone (310) 496-
3092 or (301) 496-4567.
New Books Received
Self-Assessment of Current Knowledge in Nephrology (3rd
ed), by WARREN 5, Garden City, New York, Medical Examina-
tion Publishing Co., Inc., 1982, pp. 196. Contains 500 multiple-
choice referenced questions, revised and updated, and explana-
tory answers covering a wide range of topics in nephrology.
Price: US $25.00.
Hypertension, edited by BRENNER BM and STEIN JH, New
York, Churchill Livingstone Inc., 1981, pp. 383. Price: US
$39.00. The eighth volume of Contemporary Issues in
Nephrology.
The Nephrotic Syndrome by WAGONER RD, Garden City,
New York, Medical Examination Publishing Co., Inc., 1982,
pp. 100. Price: US $15.00. Comprehensive guide to the evalua-
tion of patients presenting with the nephrotic syndrome.
Erratum
Changes during the production process may have altered the
meaning of the abstract for the following manuscript. It is
therefore reprinted below in its complete and original form:
SALANT DJ, MADAIO MP, ADLER S, STILMANT MM, COUSER
WG: Altered glomerular permeability induced by F(ab')2 and
Fab' antibodies to renal tubular epithelial antigen. Kidney mt
21:36—43, 1982.
Altered glomerular permeability induced in rats by F(ab')2 and Fab'
antibodies to renal tubular epithelial antigen. Rats injected with F(ab')2
and Fab' fragments of antibody to rat proximal tubular epithelial brush
border antigen (Fx1A) developed immediate proteinuria (F(ab')2 43.2
6.7, N = 6; Fab' 9.5 2.8, N = 5; normal 1.6 0.9 mg/d, N = 20)
which subsided over 3—5 days. This is in contrast with rats given intact
IgG anti-FxIA which did not develop immediate proteinuria (2.2 0.3
mg/d, N = 5) although glomerular binding of '251-antibody fragments
was significantly less than that of intact IgG (F(ab')2 0.11 0.01; Fab'
0.03 0.01; IgG 0.17 0.01% administered equimolar dose) at 24 hr.
No proteinuria resulted from equimolar doses of nonantibody F(ab')2
and Fab'. Less than 8% of the proteinuria induced by antibody
fragments represented injected material and 30—38% was albumin.
Immunofluorescence showed faint, diffuse glomerular capillary wall
deposits of F(ab')2 and Fab' and tubular brush border staining. Sube-
pithelial electron dense deposits and focal podocyte effacement were
seen by electron microscopy in rats given F(ab')2 antibody. Light
microscopy and collodial iron staining were normal. In this model
antibody fragments appear to interact directly with components of the
outer glomerular capillary wall to alter permeability in the absence of
recognized mediators such as complement and inflammatory cells.
